XBIO Stock Forecast: Xenetic Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.40
−9.09% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$3.6M
Ticker Nerd rank
28/ 100
Median analyst target
—
Analysts covering
—
Revenue$661K+12.0% y/y
Operating income−$972K
Net income−$930K
Free cash flow−$875K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.7%
1M
−30.0%
YTD
−35.5%
1Y
−39.4%
From 52W high
−70.0%
From 52W low
0.0%
$1.40
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Xenetic Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Accruals
57
Growth
42
Momentum
41
Issuance
31
Quality
28
Revisions
20
Value
16

Volatility (78): The share price has been relatively steady.

Value (16): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00$3.50$4.00$4.50Jan 26Apr 26Jul 26Oct 26XBIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
5 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
22 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
20 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
16 May 2023HC Wainwright & Co.DowngradeNeutral—
11 Apr 2023HC Wainwright & Co.ReiteratesBuy$4.00
2 May 2022HC Wainwright & Co.MaintainsBuy$5.00 → $4.00
11 Jan 2021HC Wainwright & Co.MaintainsBuy$2.00 → $5.00
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
20 Dec 2016Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Xenetic Biosciences, Inc. returned −39.4% against +6.9% for the S&P 500, dividends included.

XBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26XBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 63% of US stocks

Price / book
0.5×

Cheaper than 87% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
12.0%

Higher than 58% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−81.0%

Higher than 15% of US stocks

Net margin
−75.9%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−47.0%

Higher than 22% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xenetic Biosciences, Inc. has a market value of $3.6M.

  • Revenue in the twelve months to 30 June 2026: $3.3M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$2.5M, a −75.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.3M.

  • Shares outstanding: 2.3M.

  • Xenetic Biosciences, Inc. employs 2 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XBIO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XBIOXenetic Biosciences, Inc.$3.6M28
APREAprea Therapeutics, Inc.$3.2M20
LIMNLiminatus Pharma, Inc.$3.4M10
KPRXKiora Pharmaceuticals, Inc.$3.2M60
NRSNNeurosense Therapeutics Ltd.$3.2M3
AZTRAzitra, Inc.$3.1M26
SKYESkye Bioscience, Inc.$3.1M50

Take a look at XBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenetic Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XBIO

How does Ticker Nerd's model rank XBIO?

As at 21 Nov 2026, Xenetic Biosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

What is the XBIO stock forecast for 2030?

No analyst covering Xenetic Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIO are extrapolating price history, which says nothing about the business.

How has XBIO stock performed over the past year?

Xenetic Biosciences, Inc. returned -39.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenetic Biosciences, Inc. do?

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies.

Company

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies. Xenetic Biosciences is also advancing product candidates including XBIO-015 and XBIO-020 for pancreatic carcinoma and other solid tumors, along with platform technologies such as PolyXen and XCart. In addition to oncology, the company has programs that address related therapeutic areas, including anemia in chronic kidney disease through ErepoXen. Headquartered in Framingham, Massachusetts, Xenetic Biosciences serves as a specialized biotechnology player with a pipeline oriented toward novel treatment approaches across oncology and selected adjacent indications.

CEO Mr. James F. Parslow · 2 employees · United States · https://www.xeneticbio.com